Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer.
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer.
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 9, Pages 1355
Publisher
MDPI AG
Online
2019-09-12
DOI
10.3390/cancers11091355
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer
- (2019) Gillian Vandekerkhove et al. EUROPEAN UROLOGY
- PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer
- (2019) Elena Castro et al. JOURNAL OF CLINICAL ONCOLOGY
- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2019) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted next-generation sequencing (tNGS) of metastatic castrate-sensitive prostate cancer (M1 CSPC): A pilot molecular analysis in the STAMPEDE multi-center clinical trial.
- (2019) Clare Gilson et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
- (2019) Karim Fizazi et al. LANCET ONCOLOGY
- Genomic correlates of clinical outcome in advanced prostate cancer
- (2019) Wassim Abida et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy
- (2019) Hans-Jürgen Wester et al. SEMINARS IN NUCLEAR MEDICINE
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
- (2019) Ian D. Davis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
- (2019) Kim N. Chi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer
- (2019) Alex P. Hoyle et al. EUROPEAN UROLOGY
- What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis
- (2018) C L Vale et al. ANNALS OF ONCOLOGY
- Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
- (2018) M R Sydes et al. ANNALS OF ONCOLOGY
- Transdermal oestradiol as a method of androgen suppression for prostate cancer within the STAMPEDE trial platform
- (2018) Duncan C. Gilbert et al. BJU INTERNATIONAL
- Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
- (2018) Yi-Mi Wu et al. CELL
- Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies
- (2018) Gwenaelle Gravis et al. EUROPEAN UROLOGY
- Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer
- (2018) Alicia K. Morgans et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer
- (2018) Russell Z. Szmulewitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Androgen-Deprivation Therapy Is More Than Palliation in Oligometastatic Prostate Cancer
- (2018) Carlo Cattrini et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
- (2018) Christos E. Kyriakopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
- (2018) Piet Ost et al. JOURNAL OF CLINICAL ONCOLOGY
- Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial
- (2018) Kim N Chi et al. LANCET ONCOLOGY
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
- (2018) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metastatic Prostate Cancer
- (2018) Oliver Sartor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)
- (2018) Edoardo Francini et al. PROSTATE
- OC-0505: Interim results of a randomized trial of observation versus SABR for oligometastatic prostate cancer
- (2018) P. Tran et al. RADIOTHERAPY AND ONCOLOGY
- Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure
- (2018) Susan Slovin et al. JAMA Oncology
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis
- (2018) Susan Feyerabend et al. EUROPEAN JOURNAL OF CANCER
- Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial
- (2018) Liselotte M.S. Boevé et al. EUROPEAN UROLOGY
- KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
- (2018) Johann S. De Bono et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA4Effects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate cancer
- (2018) A P Hoyle et al. ANNALS OF ONCOLOGY
- Oligometastatic prostate cancer: Reality or figment of imagination?
- (2018) Corey C. Foster et al. CANCER
- Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma
- (2018) Bimal Bhindi et al. EUROPEAN UROLOGY
- Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
- (2018) Wassim Abida et al. JAMA Oncology
- Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss
- (2018) Johann S. de Bono et al. CLINICAL CANCER RESEARCH
- The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis
- (2017) Björn Löppenberg et al. EUROPEAN UROLOGY
- Local Therapy Improves Survival in Metastatic Prostate Cancer
- (2017) Sami-Ramzi Leyh-Bannurah et al. EUROPEAN UROLOGY
- Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide
- (2017) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2017) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cytoreductive Prostatectomy for Metastatic Prostate Cancer: First Lessons Learned From the Multicentric Prospective Local Treatment of Metastatic Prostate Cancer (LoMP) Trial
- (2017) Filip Poelaert et al. UROLOGY
- Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications
- (2017) Naoki Terada et al. Therapeutic Advances in Medical Oncology
- Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform
- (2016) Silke Gillessen et al. EUROPEAN UROLOGY
- Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer
- (2016) Heather H. Cheng et al. EUROPEAN UROLOGY
- Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial
- (2016) Gwenaelle Gravis et al. EUROPEAN UROLOGY
- Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details
- (2016) Maha Hussain et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data
- (2016) Claire L Vale et al. LANCET ONCOLOGY
- Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer
- (2016) Akash Kumar et al. NATURE MEDICINE
- Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
- (2016) Alexander W. Wyatt et al. JAMA Oncology
- The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma
- (2015) Jonathan I. Epstein et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Risk Stratification in Hormone-sensitive Metastatic Prostate Cancer: More Questions than Answers
- (2015) Sarah P. Psutka et al. EUROPEAN UROLOGY
- Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model
- (2015) Gwenaelle Gravis et al. EUROPEAN UROLOGY
- Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis
- (2015) Raj Satkunasivam et al. JOURNAL OF UROLOGY
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer
- (2014) S Merson et al. BRITISH JOURNAL OF CANCER
- Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial
- (2014) Gerhardt Attard et al. EUROPEAN UROLOGY
- Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance)
- (2014) Matthew R. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
- (2013) Gwenaelle Gravis et al. LANCET ONCOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials
- (2009) David P Dearnaley et al. LANCET ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started